The Hemerion team has been shaped over 10 years of research within Inserm, the University of Lille and the Lille University Hospital. It brings together complementary profiles: physicists and surgeons specialized in oncology. We develop innovative therapeutic solutions, at the crossroads of surgery and photonics. The scientific and medical team is complemented by experienced professionals in business management, regulatory functions and clinical development.


Maximilien Vermandel
LikedIn icon

Maximilien Vermandel,

PhD, Physics

CEO, Founder

  • Over 18 years of research in physics and neurosurgery
  • Head of the medical physics dept of the University Hospital of Lille (France)
  • Deputy director of OncoThAI Lab (Inserm U1189)
  • Program manager for General Electric Healthcare joint research program
  • Team Leader of the glioblastoma research and development program at OncoThAI Lab
Clément Dupont
LikedIn icon

Clément Dupont,

PhD, Physics

CTO, Co-Founder

  • Management of preclinical investigations in glioblastoma studies
  • Designer of the medical devices used in the first-in-human clinical trial evaluating the Hemerion Technology
  • Deputy team leader of the Synaps project from OncoThAI Lab
Michel Andraud
LikedIn icon

Michel Andraud,

MSc, Business School

CFO, Co-Founder

  • Transition manager over 15 years after 18 years as CFO in various industrial companies, (Entrelec, gmp-orphan SA, DI Finances) and in mergers and acquisitions
  • Cash management oriented
  • CFO of OP2 drugs SA

Scientific Board

LikedIn icon

Pr. Nicolas Reyns,

PhD, MD, Neurosurgery


  • Head of the neurosurgery oncology dept of the Univ. Hosp. of Lille
  • Co-inventor of the Hemerion technology
  • Over 100 scientific papers
Pr. Serge Mordon
LikedIn icon

Pr. Serge Mordon,

PhD, Physics


  • Full time researcher in laser therapy over 30 years at Inserm
  • Former Director of OncoThAI Lab (Inserm U1189)
  • Over 300 scientific papers
Costas Hadjipanayis
LikedIn icon

Pr. Costas G. Hadjipanayis,

PhD, MD, Neurosurgery

  • Site Chair of Neurosurgery, Mount Sinai (NYC, NY, USA)
  • Director of Neurosurgical Oncology for the Mount Sinai Health System
  • Helped lead the FDA approval of Gleolan
  • Over 100 scientific papers